Xarelto Is The Pharma Watchword In Bayer's 3Q Update

26 Oct 2017

Despite Bayer AG's third quarter earnings call being heavily dominated by talk of the company's ongoing Monsanto acquisition and its recent deconsolidation of material science company Covestro, Xarelto stood out as the hot topic within the German firm's pharma division.

blood clot — Bayer targets 2017 regulatory filings for Xarelto in coronary artery and peripheral arterial disease

Xarelto Is The Pharma Watchword In Bayer's 3Q Update

More from Earnings

More from Business